Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


20.05.2024

1 AJR Am J Roentgenol
2 BJU Int
1 BMC Cancer
1 Br J Radiol
1 Cancer
1 Cancer Lett
1 Eur J Radiol
10 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
2 J Magn Reson Imaging
1 J Urol
1 JAMA
1 Oncogene
1 Oncol Rep
1 PLoS One
4 Prostate
1 Radiol Imaging Cancer
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SAVIR-BARUCH B, Parent E
    Beyond the AJR: PET/MRI Using (68)Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment.
    AJR Am J Roentgenol. 2024 May 15. doi: 10.2214/AJR.24.31412.
    PubMed        


    BJU Int

  2. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
    Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
    BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
    PubMed         Abstract available

  3. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
    A review of vitamin use for the prevention or treatment of prostate cancer.
    BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
    PubMed        


    BMC Cancer

  4. CHE B, Yuan S, Zhang H, Zhai J, et al
    Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
    BMC Cancer. 2024;24:586.
    PubMed         Abstract available


    Br J Radiol

  5. NAIK M, Khan SR, Lewington V, Challapalli A, et al
    Imaging and therapy in prostate cancer using PSMA radioligands.
    Br J Radiol. 2024 May 11:tqae092. doi: 10.1093.
    PubMed         Abstract available


    Cancer

  6. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed         Abstract available


    Cancer Lett

  7. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    PubMed         Abstract available


    Eur J Radiol

  8. FRANSEN SJ, Roest C, Van Lohuizen QY, Bosma JS, et al
    Using deep learning to optimize the prostate MRI protocol by assessing the diagnostic efficacy of MRI sequences.
    Eur J Radiol. 2024;175:111470.
    PubMed         Abstract available


    Eur Urol

  9. FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
    Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
    PubMed        

  10. STROOMBERG HV, Brasso K, Roder A
    Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
    Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
    PubMed        

  11. KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
    Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
    Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  12. MERSEBURGER AS, Chowdhury S, Bahl A
    Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
    Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
    PubMed        

  13. CHIN JL
    Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
    Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
    PubMed        

  14. KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
    The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
    Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  15. OKOLI S, Okoli O, Ding H, Adeleke S, et al
    Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
    Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
    PubMed        

  16. WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
    Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
    Eur Urol. 2023;84:491-502.
    PubMed         Abstract available

  17. GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
    Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
    Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
    PubMed        

  18. PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
    Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
    Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
    PubMed        


    Int J Cancer

  19. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
    Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Int J Cancer. 2024;155:314-323.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  20. GLOWA C, Bendinger AL, Euler-Lange R, Peschke P, et al
    Irradiation with carbon ions effectively counteracts hypoxia-related radioresistance in a rat prostate carcinoma.
    Int J Radiat Oncol Biol Phys. 2024 May 13:S0360-3016(24)00627.
    PubMed         Abstract available


    J Clin Oncol

  21. SPRATT DE
    Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
    J Clin Oncol. 2024 May 14:JCO2302689. doi: 10.1200/JCO.23.02689.
    PubMed        

  22. EINSTEIN DJ, Regan MM, Stevens JS, McDermott DF, et al
    Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
    J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279.
    PubMed         Abstract available

  23. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445.
    PubMed         Abstract available


    J Magn Reson Imaging

  24. ZABIHOLLAHY F, Miao Q, Naim S, Sonni I, et al
    Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men.
    J Magn Reson Imaging. 2024 May 15. doi: 10.1002/jmri.29397.
    PubMed         Abstract available

  25. MUSALL BC, Schweitzer MD
    Editorial for: "Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men".
    J Magn Reson Imaging. 2024 May 16. doi: 10.1002/jmri.29411.
    PubMed        


    J Urol

  26. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    PubMed         Abstract available


    JAMA

  27. HARRIS E
    Urine-Based Test Could Help Identify Aggressive Prostate Cancer.
    JAMA. 2024 May 17. doi: 10.1001/jama.2024.8424.
    PubMed        


    Oncogene

  28. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
    Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
    Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
    PubMed         Abstract available


    Oncol Rep

  29. PAN J, Tong F, Ren N, Ren L, et al
    Role of N(6)?methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
    Oncol Rep. 2024;51:88.
    PubMed         Abstract available


    PLoS One

  30. AZUR RAG, Olarte KCV, Ybanez WS, Ocampo AMM, et al
    CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
    PLoS One. 2024;19:e0300413.
    PubMed         Abstract available


    Prostate

  31. MACKAY S, Oduor IO, Burch TC, Main BP, et al
    Increased alpha2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer.
    Prostate. 2024 May 12. doi: 10.1002/pros.24724.
    PubMed         Abstract available

  32. NAKAI Y, Tanaka N, Asakawa I, Ohnishi K, et al
    Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
    Prostate. 2024 May 12. doi: 10.1002/pros.24744.
    PubMed         Abstract available

  33. BUTTNER T, Klumper N, Weiten R, Lossin P, et al
    Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2024 May 15. doi: 10.1002/pros.24747.
    PubMed         Abstract available

  34. ABEDALI Z, Woloshuk A, Cary C, Boris RS, et al
    Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer.
    Prostate. 2024 May 16. doi: 10.1002/pros.24743.
    PubMed         Abstract available


    Radiol Imaging Cancer

  35. HU C, Qiao X, Huang R, Hu C, et al
    Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer.
    Radiol Imaging Cancer. 2024;6:e230143.
    PubMed         Abstract available


    Urology

  36. VAN VELTHOVEN R, Diamand R, Mozer P, Barry de Longchamp N, et al
    Letter to the Editor on "Comparison in Detection Rate of Clinically Significant Prostate Cancer Between Microultrasound-guided Prostate Biopsy (ExactVu) and Multiparametric Resonance Imaging-guided Prostate Biopsy (Koelis System)".
    Urology. 2024 May 8:S0090-4295(24)00346-7. doi: 10.1016/j.urology.2024.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.